JP5977478B2 - 小麦発酵抽出物配合物 - Google Patents
小麦発酵抽出物配合物 Download PDFInfo
- Publication number
- JP5977478B2 JP5977478B2 JP2009102517A JP2009102517A JP5977478B2 JP 5977478 B2 JP5977478 B2 JP 5977478B2 JP 2009102517 A JP2009102517 A JP 2009102517A JP 2009102517 A JP2009102517 A JP 2009102517A JP 5977478 B2 JP5977478 B2 JP 5977478B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- wheat
- extract
- dyslipidemia
- fermented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims description 39
- 241000209140 Triticum Species 0.000 title claims description 36
- 235000021307 Triticum Nutrition 0.000 title claims description 36
- 239000000203 mixture Substances 0.000 title claims description 12
- 238000000855 fermentation Methods 0.000 title claims description 8
- 230000004151 fermentation Effects 0.000 title claims description 8
- 238000009472 formulation Methods 0.000 title claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 24
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 24
- 206010012601 diabetes mellitus Diseases 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 15
- 239000008103 glucose Substances 0.000 claims description 15
- 241000051611 Salacia oblonga Species 0.000 claims description 14
- 235000013312 flour Nutrition 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 4
- 241000545263 Salacia <hydroid> Species 0.000 claims description 3
- 239000003788 bath preparation Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 description 17
- 102000007330 LDL Lipoproteins Human genes 0.000 description 9
- 108010007622 LDL Lipoproteins Proteins 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 102000015779 HDL Lipoproteins Human genes 0.000 description 7
- 108010010234 HDL Lipoproteins Proteins 0.000 description 7
- 235000019577 caloric intake Nutrition 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 241000588912 Pantoea agglomerans Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- -1 cyclic oligosaccharide Chemical class 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000008474 Pimenta dioica Species 0.000 description 1
- 235000006990 Pimenta dioica Nutrition 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- SOWRVDSZMRPKRG-YRPOCYRVSA-N S(=O)(=O)(O[C@@H](CO)[C@@H](C[S@+]1[C@@H]([C@H]([C@@H](C1)O)O)CO)O)[O-] Chemical compound S(=O)(=O)(O[C@@H](CO)[C@@H](C[S@+]1[C@@H]([C@H]([C@@H](C1)O)O)CO)O)[O-] SOWRVDSZMRPKRG-YRPOCYRVSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000019742 Vitamins premix Nutrition 0.000 description 1
- DDEDPQYNISJXLF-XTMYEIJHSA-N [(z)-4-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-3-benzoylsulfanylpent-3-enyl] benzoate;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(=O)OCC\C(SC(=O)C=1C=CC=CC=1)=C(/C)N(C=O)CC1=CN=C(C)N=C1N DDEDPQYNISJXLF-XTMYEIJHSA-N 0.000 description 1
- HEAFLBOWLRRIHV-UHFFFAOYSA-N [Na].[P] Chemical compound [Na].[P] HEAFLBOWLRRIHV-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940043357 mangiferin Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本件において、我々は、小麦発酵抽出物とサラシア・オブロンガの混合品が単独では得られない効果を発現できることを見出し、安全で生活習慣病予備群に有効な医薬部外品、食品、機能性食品、ペット用飼料を提供できる。
免疫賦活作用を持つ物質としての小麦発酵抽出物と血糖値を低下させるサラシア・オブロンガの組み合わせが新規である。
空腹時血糖が100〜125mg/dlの被験者群(Aグループ:糖尿病予備群)と、空腹時血糖が100mg/dl未満で中性脂肪 150mg/dl以上、HDLコレステロール40mg/dl未満、LDLコレステロール 120mg/dl以上のいずれかに該当する被験者群(Bグループ:脂質異常症予備群)に分け、それぞれ小麦発酵抽出物とサラシア・オブロンガ混合群(S)とサラシア・オブロンガ群(P)、小麦発酵抽出物群(Y)に分けた。各群60日間て試験を行った。それぞれの群の被験者は、1回1包を1日2回自由に摂取し、試飲タイミングと体調をセルフチェックシートに毎日記録してもらった。試験前、試験中間(30日目頃)、及び試験後に、血液検査、一般身体調査、アンケート調査を提携病院にて実施した。統計解析は、対応のあるt検定を行いp<0.05を有意とした。
Aグループ:(S群)男性5名、女性2名、合計7名。(P群)男性4名、女性2名、合計6名。(Y群)男性4名、女性2名、合計6名。
Bグループ:(S群)男性8名、女性6名、合計14名。(P群)男性7名、女性7名、合計14名。(Y群)男性7名、女性6名、合計13名。
Aグループ:
(S群)男性49.2±6.3歳、女性51.0±5.7歳、合計49.7±5.7歳。
(P群)男性49.5±7.5歳、女性47.0±5.7歳、合計48.7±6.5歳。
(Y群)男性47.3±9.5歳、女性48.5±12.0歳、合計47.7±9.2歳。
Bグループ:
(S群)男性48.4±7.6歳、女性51.5±6.7歳、合計49.7±7.2歳。
(P群)男性45.6±5.4歳、女性50.6±10.1歳、合計48.1±8.2歳。
(Y群)男性48.1±65.9歳、女性46.2±5.9歳、合計47.2±6.0歳。
(1) パントエア・アグロメランスは小麦粉より定法に従い単離する。なお、一度、単離同定すれば、この菌を50%グリセロール等で保存が可能である。
(2) 0.05〜5%の食塩、0.005〜1モルのリン酸緩衝液、または、混合塩類溶液(0.5〜10%のリン酸第二ナトリウム、0.05〜5%のリン酸第一カリウム、0.05から5%の塩化ナトリウム、0.05〜5%の塩化アンモニウム)等を調製する。
(3) 0.05〜10%の濃度になるように小麦粉を水に懸濁する。
(4) 0.2〜3モルの塩化マグネシウム溶液を調製する。
(5) 0.2〜3モルの塩化カルシウム溶液を調製する。
(6) 2から5を場合によってはオートクレーブ等で滅菌操作を行う。
(7) 2から5を適量混合し、水を加え、0.1〜5%の小麦粉を含む懸濁液とする。場合によってはアルカリ溶液や酸性溶液を加えpHを中性にする。
(8) 7に場合によっては培地1リットルあたり10〜50000単位アミラーゼを加えて10℃から80℃で1〜24時間保温して、小麦でんぷんを部分消化させるのもよい。
(9) 7乃至8に1で単離したパントエア・アグロメランスを添加する。
(10) 9を1〜40℃で発酵させる。場合によっては静置や震盪してもよい。また、数時間おきに撹拌を行うことでもよい。
(11) 10を6時間から一週間発酵させる。発酵が進むと小麦粉水溶液が黄色に着色してくる。
(12) 11の発酵途中に適宜アルカリ溶液を加え、pHを中性にすることや、小麦粉懸濁液や無機塩類を添加することもよい。
(13) 発酵を終了させ、遠心分離(1000〜5000rpm、10〜60分間)等の操作により固形分を沈殿物として回収する。
(14) 13を水または塩類緩衝液等で懸濁し、これを80〜140℃で10分から6時間加熱処理する。さらに、これを遠心分離や活性炭処理、濾過すること等で、固形分を除去してもよい。除去した沈殿に再度水や緩衝液を加え、加熱抽出を数回繰り返してもよい。これを乾燥させれば粉末とすることも出来る。
(15) 14で製造した小麦発酵抽出物は用途によってはさらに簡便な精製を追加することが出来る。すなわち、14の抽出物に、最終濃度0.05〜1モル/lになるように塩化ナトリウム等の塩を加え、その後、エタノール等の溶媒を抽出物の1〜3倍量添加すると沈殿が生じる。これを遠心分離機等で回収してもよい。この沈殿をさらに、エタノール等の溶媒で洗浄してもよい。これを乾燥させれば、粉末とすることも出来る。
サンプルは、ほうじ茶エキス、難消化性デキストリン、サラシア・オブロンガエキス、小麦発酵抽出物(製造方法(14)の粉末)(20mg)、ビタミンプレミックス(ジベンゾイルチアミン塩酸塩0.32mg、リボフラビンリン酸エステルナトリウム0.27mg、ニコチン酸アミド1.63mg、パントテン酸カルシウム0.96mg、ピリドキシン塩酸塩0.28mg、シアノコバラミン0.75μg、L-アスコルビン酸(VC)7.5mg)、オリゴ糖、環状オリゴ糖を混合した。これを1包あたり1.0グラムになるように分包した。
各群のHbA1cの変化を測定した。各人の測定前の測定値を1として60日の値を比率で示した。なお、HbA1c(ヘモグロビンA1C)とは、ヘモグロビンと糖が結合したもので、HtA1Cを調べることにより過去1〜3ヶ月程度の血糖値の平均値を測定する事ができる指標として、活用されている。
各群のLDLの変化を測定した。各人の測定前の測定値を1として30日及び60日の値を比率で示した。
各群のHDLの変化を測定した。各人の測定前の測定値を1として30日または60日の値を比率で示した。
Claims (3)
- 小麦粉を植物に共生する通性嫌気性グラム陰性菌によって発酵させて、同時に該通性嫌気性グラム陰性菌を培養することによって得られる抽出物(以下、「小麦発酵抽出物」と言う。)及びサラシア属の植物の抽出物を含むことを特徴とする脂質異常症予備群における血糖値改善用、かつ、糖尿病予備群における脂質異常症改善用の小麦発酵抽出物配合物。
- 小麦発酵抽出物及びサラシア・オブロンガを含むことを特徴とする脂質異常症予備群における血糖値改善用、かつ、糖尿病予備群における脂質異常症改善用の小麦発酵抽出物配合物。
- 前記小麦発酵抽出物配合物は、医薬品、ペット用医薬品、医薬部外品、食品、機能性食品、ペット用飼料又は浴用剤であることを特徴とする請求項1又は2記載の小麦発酵抽出物配合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009102517A JP5977478B2 (ja) | 2009-04-21 | 2009-04-21 | 小麦発酵抽出物配合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009102517A JP5977478B2 (ja) | 2009-04-21 | 2009-04-21 | 小麦発酵抽出物配合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010254578A JP2010254578A (ja) | 2010-11-11 |
JP5977478B2 true JP5977478B2 (ja) | 2016-08-24 |
Family
ID=43315937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009102517A Active JP5977478B2 (ja) | 2009-04-21 | 2009-04-21 | 小麦発酵抽出物配合物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5977478B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102697863B (zh) * | 2012-01-17 | 2014-02-26 | 李付德 | 一种治疗阴虚单相型低压高高血压的中药组合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH092963A (ja) * | 1995-06-20 | 1997-01-07 | Yakult Honsha Co Ltd | マオウより得られる糖質分解酵素阻害物質及びそれを含有するダイエット食品 |
JP2001163795A (ja) * | 1999-12-07 | 2001-06-19 | Gunze Ltd | α−グルコシダーゼ阻害剤 |
JP2001181194A (ja) * | 1999-12-22 | 2001-07-03 | Gunze Ltd | α−グルコシダーゼ阻害剤 |
JP2005008572A (ja) * | 2003-06-19 | 2005-01-13 | Yakult Honsha Co Ltd | リパーゼ阻害剤 |
AU2004276123B2 (en) * | 2003-09-26 | 2008-06-26 | Biomedical Research Group Inc. | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract |
-
2009
- 2009-04-21 JP JP2009102517A patent/JP5977478B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2010254578A (ja) | 2010-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Barrett et al. | A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): a review of clinical studies on weight loss and glycemic control | |
Hayashi et al. | Study on the postprandial blood glucose suppression effect of D-psicose in borderline diabetes and the safety of long-term ingestion by normal human subjects | |
Johnston et al. | Examination of the antiglycemic properties of vinegar in healthy adults | |
Rabbani et al. | Clinical studies in persistent diarrhea: dietary management with green banana or pectin in Bangladeshi children | |
Williams et al. | Extract of Salacia oblonga lowers acute glycemia in patients with type 2 diabetes | |
Schneeman | Gastrointestinal physiology and functions | |
Yamada et al. | Effect of bread containing resistant starch on postprandial blood glucose levels in humans | |
US6916796B2 (en) | Use of pullulan as a slowly digested carbohydrate | |
CN101454016A (zh) | 豆豉提取物的使用方法和营养组合物 | |
US20030082168A1 (en) | Compositions and methods for facilitating weight loss | |
CN113519631B (zh) | 一种辅助降血糖的低血糖负荷中老年调制乳粉及制备方法 | |
Sivieri et al. | Insights on β-glucan as a prebiotic coadjuvant in the treatment of diabetes mellitus: A review | |
US20140342042A1 (en) | Method of lowering glycemic index of foods | |
CN115177632A (zh) | 一种具有通便作用的益生元组合物 | |
CN109757727A (zh) | 适用于肠型ⅱ人群的餐后血糖调节与预防的膳食组合物 | |
JP2019210269A (ja) | 糖尿疾患の治療用組成物 | |
CN112931883A (zh) | 一种益生元组合物及其制备方法和应用 | |
JP5977478B2 (ja) | 小麦発酵抽出物配合物 | |
EP2294932B1 (en) | Carbohydrate mixture and the use thereof for preparing a product for oral or enteral nutrition | |
Fujita et al. | Efficacy and safety of Chinese black tea (Pu-Ehr) extract in healthy and hypercholesterolemic subjects | |
WO2005041995A1 (ja) | α-グルコシダーゼ活性阻害剤 | |
WO2004014159A1 (en) | Method of lowering glycaemic index of foods | |
Ikem et al. | A controlled comparison of the effect of a high fiber diet on the glycemic and lipid profile of Nigerian clinic patients with type 2 diabetes | |
JP4838894B2 (ja) | 糖代謝改善剤 | |
Mathers et al. | Digestion and metabolism of carbohydrates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120402 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130828 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140820 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141007 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20141121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160425 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160722 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5977478 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |